ARCB vs EPAC

ArcBest Corporation's Piotroski F-Score of 4/9 indicates weak financial health, signaling deterioration in operational efficiency and profitability. The absence of an Altman Z-Score raises concern about potential distress risk, especially given a current ratio of 0.95 and quick ratio of 0.79, both below safe thresholds. Despite a seemingly attractive forward P/E of 11.68, the company exhibits negative revenue growth (-2.90% YoY) and severe earnings declines (YoY EPS down 72.9%), undermining long-term sustainability. The Graham Number of $58.46 suggests a defensive fair value, yet the stock trades at $84.87—over 44% above this benchmark—indicating significant overvaluation. Analysts' 'buy' recommendation appears misaligned with deteriorating fundamentals.

EPAC presents a stark contrast between a healthy balance sheet and a severely overvalued market price. While the Piotroski F-Score of 4/9 indicates stable financial health and the company maintains strong margins and low debt, the stock is trading at a massive premium to its Graham Number ($16.82) and Intrinsic Value ($11.13). This valuation gap is exacerbated by negative earnings growth (-18.4% YoY) and a completely bearish technical trend (0/100). Despite strong ROE, the lack of earnings momentum and the significant distance from defensive fair value suggest limited upside and high downside risk.